**Supplementary Materials for:**

*The effects of polygenic risk for psychiatric disorders and smoking behaviour on psychotic experiences in UK Biobank*

**Supplementary methods**

|  |  |
| --- | --- |
| Page 2 - | **Supplementary Table 1.** Phenotype definition for lifetime delusions. |
| Page 2 - | **Supplementary Table 2.** Phenotype definition for lifetime hallucinations. |
| Page 3 - | **Supplementary Table 3.** Phenotype definition for any lifetime psychotic experience. |
| Page 4 - | **Supplementary Table 4.** Phenotype definition for diagnosis of depression, ADHD and psychotic disorders. |
| Page 6 - | **Supplementary Table 5.** List of antidepressants used for defining symptoms of depression. |
| Page 7 - | **Supplementary Table 6.** Number of individuals excluded as part of the quality control of genetic data. |
| Page 8 - | **Polygenic score approach** |
| Page 9 - | **PRS power calculation** |

**Supplementary results**

|  |  |
| --- | --- |
| Page 10 - | **Supplementary Table 7.** Phenotypic correlations between smoking and psychotic experiences after quality control. |
| Page 11 - | **Supplementary Figure 1**. Prediction of psychotic experiences in UKB using PRSs for schizophrenia (Panel A), depression (Panel B) and ADHD (Panel C). |
| Page 12 - | **Supplementary Figure 2:** Prediction of smoking behaviours in UKB using PRSs for schizophrenia (Panel A), depression (Panel B) and ADHD (Panel C). |
| Page 13 - | **Supplementary Table 8**. Interaction effects between PRSs and smoking status (never vs former vs current) on psychotic experiences (delusions, hallucinations or any of these two). |
| Page 15 - | **Supplementary Table 9.** Number of individuals with psychotic disorders that were excluded. |
| Page 15 - | **Supplementary Figure 3**. Sensitivity analyses, excluding individuals with diagnosis of psychotic disorders. |
| Page 16 - | **Supplementary Table 10**. Interaction effects between PRSs and smoking status (never vs former vs current) on delusions. |
| Page 17 - | **Supplementary Table 11**. Interaction effects between PRSs and maternal smoking on psychotic experiences (delusions, hallucinations or any of these two). |
| Page 18 - | **Supplementary Table 12**. Interaction effects between PRSs and the number of packs smoked per year on psychotic experiences (delusions, hallucinations or any of these two). |

**Supplementary methods**

**Supplementary Table 1.** Phenotype definition for lifetime delusions.

|  |  |  |  |
| --- | --- | --- | --- |
| **Description** | **Fields and codes** | **N** | **Notes and references** |
| **Case: Delusions ever**.  Endorsed possible delusion | Believed unreal conspiracy 20468 = Yes  OR  Believed unreal communication or signs f.20474 = yes | 2 067 | Code adapted from Davis et al (1) |
| **Control: Unusual experience ever**. | Hear unreal voice f.20463 = no  AND  Saw unreal vision f.20471 = no  AND  Believed unreal conspiracy 20468 = no  AND  Believed unreal communication or signs f.20474 = no | 155 182 |
| Number of controls: **155 182 individuals**  Number of cases: **2 067 individuals** | | | |

**Supplementary Table 2.** Phenotype definition for lifetime hallucinations.

|  |  |  |  |
| --- | --- | --- | --- |
| **Description** | **Fields and codes** | **N** | **Notes and references** |
| **Case: Hallucinations ever**.  Endorsed possible hallucination | Hear unreal voice f.20463 = yes  OR  Saw unreal vision f.20471 = yes | 6 689 | Code adapted from Davis et al (1) |
| **Control: Unusual experience ever**. | Hear unreal voice f.20463 = no  AND  Saw unreal vision f.20471 = no  AND  Believed unreal conspiracy 20468 = no  AND  Believed unreal communication or signs f.20474 = no | 150 336 |
| Number of controls: **150 336 individuals**  Number of cases: **6 689 individuals** | | | |

**Supplementary Table 3.** Phenotype definition for any lifetime psychotic experience.

|  |  |  |  |
| --- | --- | --- | --- |
| **Description** | **Fields and codes** | **N** | **Notes and references** |
| **Case: Unusual experience ever**.  Endorsed possible hallucination or delusion | Hear unreal voice f.20463 = yes  OR  Saw unreal vision f.20471 = yes  OR  Believed unreal conspiracy 20468 = yes  OR  Believed unreal communication or signs f.20474 = yes | 7 803 | Code adapted from Davis et al, 2018 (1) |
| **Control: Unusual experience ever**. | Hear unreal voice f.20463 = no  AND  Saw unreal vision f.20471 = no  AND  Believed unreal conspiracy 20468 = no  AND  Believed unreal communication or signs f.20474 = no | 149 289 |  |
| Number of controls: **149 289 individuals**  Number of cases: **7 803 individuals** | | | |

**Supplementary Table 4.** Phenotype definition for diagnosis of depression, ADHD and psychotic disorders.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Origin** | **Description** | **Fields and codes** | **N** | **Notes and references** |
| Baseline interview.  Full cohort | Depression  Post-natal depression | For item f.20002, reporting diagnosis of depression (coded=1286), OR post-natal depression (coded=1531) | 28 472 |  |
| Treatment medication code.  Full cohort | Depression | Presence of antidepressants in treatment medication code (f.20003). | 36 786 | Antidepressants in Supplementary Table 5 |
| In-hospital with primary or secondary diagnosis of Mental Health disorders.  Full cohort | Depression | Main and secondary diagnoses from hesin.tsv and hesin\_diag10.tsv files.  Included all the items from categories corresponding to depressive episode or recurrent depressive disorder: 'F320','F321','F322','F323','F328','F329','F330','F331','F332','F333','F334','F338','F339' | 4 086 |  |
| Mental Health Questionnaire Screening | Depression (ever) | Persistent sadness (f.20446) = Yes OR Loss of interest (f.20441) = Yes  AND  How much of day (f.20436) = Most of day or All day long  AND  Did you feel this way (f.20439) = Almost every day or every day  AND  Impairment (f.20440) = Somewhat or A lot  AND  Total number of symptoms endorsed (core and others) >= 5  Persistent sadness (core) f.20446; Loss of interest (core) f.20441; Tired or low energy f.20449; Gain or loss of weight f.20536 = Gain, Loss or Gain and loss; Sleep change f.20532; Trouble concentrating f.20435; Feeling worthless f.20450; Thinking about death f.20437 | 37 430 | CIDI-SF (Composite International Diagnostic Interview – Short Form), depression module, lifetime version. Scored based on DSM definition of major depressive disorder (2) |
| Mental Health Questionnaire – Self-reported clinician diagnoses | Depression | For item f. 20544 the array of 16 columns screened for: ‘Depression’ | 33 422 |  |
| **Combine Above** | **Lifetime diagnosis of depression** | | **88 976** |  |
| Mental Health Questionnaire – Self-reported clinician diagnoses | ADHD | For item f. 20544 the array of 16 columns screened for diagnosis of Attention deficit or attention deficit and hyperactivity disorder (ADD/ADHD) | 133 |  |
| **Combine Above** | **Lifetime diagnosis of ADHD** | | **133** |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Origin** | **Description** | **Fields and codes** | **N** |  |
| Mental Health Questionnaire | Self-reported physician diagnosis of schizophrenia, mania, hypomania, bipolar or manic depression or any other type of psychotic disorder | Schizophrenia (coded=2 in f.20544) OR  any other type of psychosis or psychotic illness (coded=3 in f.20544) | Schizophrenia N = 157  Any other type of psychosis or psychotic illness N = 604  Mania, hypomania, bipolar or manic-depression N = 837 |  |
| Hospital admissions | Schizophrenia, schizotypal and delusional disorders  OR  Mood [affective] disorders | Main and secondary diagnoses from hesin.tsv and hesin\_diag10.tsv files.  **ICD-10 codes:**  'F200','F201','F202','F203','F204','F205','F206','F208','F209', 'F21','F220','F228','F229','F230','F231','F232','F233','F238','F239', 'F24', 'F250','F251','F252','F258','F259','F28','F29','F300','F301','F302','F308','F309','F310','F311','F312','F313','F314','F315','F316','F317','F318','F319' | N = 1 894 | ICD-10 codes obtained from UK Biobank: <http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=41202> |
| Baseline assessment centre | Self-reported diagnosis of schizophrenia or mania/bipolar disorder/ manic depression in oral interview | Reporting diagnosis of schizophrenia (coded=1289) OR mania/bipolar disorder/ manic depression (coded=1291) for item f.20002 | N = 1 995 |  |
| Death records | Schizophrenia, schizotypal and delusional disorders  OR  Mood [affective] disorders | Main and secondary causes of death from death record files  **ICD-10 codes:**  'F200','F201','F202','F203','F204','F205','F206','F208','F209', 'F21','F220','F228','F229','F230','F231','F232','F233','F238','F239', 'F24', 'F250','F251','F252','F258','F259','F28','F29','F300','F301','F302','F308','F309','F310','F311','F312','F313','F314','F315','F316','F317','F318','F319' | N = 13 |  |
| **Combine Above** | **Lifetime diagnosis of psychotic disorders** | | **4 847** |  |

|  |  |
| --- | --- |
| **UKB drug code** | **Drug name** |
| 1140879616 | amitriptyline |
| 1140921600 | citalopram |
| 1140879540 | fluoxetine |
| 1140867878 | sertraline |
| 1140916282 | venlafaxine |
| 1140909806 | dosulepin |
| 1140867888 | paroxetine |
| 1141152732 | mirtazapine |
| 1141180212 | escitalopram |
| 1140879634 | trazodone |
| 1140867876 | prozac |
| 1140882236 | seroxat |
| 1141190158 | cipralex |
| 1141200564 | duloxetine |
| 1140867726 | lofepramine |
| 1140879620 | clomipramine |
| 1140867818 | nortriptyline |
| 1140879630 | imipramine |
| 1140879628 | dothiepin |
| 1141151946 | cipramil |
| 1140867948 | amitriptyline |
| 1140867624 | prothiaden |
| 1140867756 | trimipramine |
| 1140867884 | lustral |
| 1141151978 | reboxetine |
| 1141152736 | zispin |
| 1141201834 | cymbalta |
| 1140867690 | anafranil |
| 1140867640 | doxepin |
| 1140867920 | moclobemide |
| 1140867850 | phenelzine |
| 1140879544 | fluvoxamine |
| 1141200570 | yentreve |
| 1140867934 | triptafen |
| 1140867758 | surmontil |
| 1140867914 | tranylcypromine |
| 1140867820 | allegron |
| 1141151982 | edronax |
| 1140882244 | molipaxin |
| 1140879556 | mianserin |
| 1140867852 | nardil |
| 1140867860 | faverin |
| 1140917460 | nefazodone |
| 1140867938 | amitriptyline+chlordiazepoxide |
| 1140867856 | isocarboxazid |
| 1140867922 | manerix |
| 1140910820 | maoi |
| 1140882312 | sinequan |
| 1140867944 | tranylcypromine+trifluoperazine |
| 1140867784 | ludiomil |
| 1140867812 | norval |
| 1140867668 | tryptizol |
| 1140867940 | fluphenazine |

**Supplementary Table 5.** List of antidepressants used for defining symptoms of depression.

**Supplementary Table 6.** Number of individuals excluded as part of the quality control of genetic data.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Phenotype** | **N with phenotype available** | **Non-European ancestry / Genetic data not available / QC exclusion** | **Related individuals excluded** | **Sample size after quality control** |
| **Maternal smoking around birth** | 432 897 | 37 159 | 26 458 | No = 255 386  Yes = 113 894  **Total = 369 280** |
| **Smoking status** | 499 590 | 40 842 | 33 342 | Never = 229 221  Former = 151 605  Current = 44 580  **Total = 425 406** |
| **Pack smoked/year** | 150 950 | 8 575 | 4 620 | Mean = 23.5  Median = 19.2  **Total = 137 755** |
| **Any psychotic experience** | 157 357 | 8 010 | 4 233 | *Controls* = 137 695  *Cases* = 7 419  **Total = 145 114** |
| **Hallucinations** | 157 025 | 7 978 | 4 229 | *Controls* = 138 654  *Cases* = 6 164  **Total = 144 818** |
| **Delusions** | 157 249 | 7 992 | 4 233 | *Controls* = 143 145  *Cases* = 1 879  **Total = 145 024** |

**Polygenic score approach**

We calculated polygenic risk scores (PRSs) using summary statistics from GWAS meta-analyses for depression (3), ADHD (4) and schizophrenia (5).

**a) Depression**: A recent GWAS meta-analysis including 246 363 cases and 561 190 controls identified 102 significant independent loci associated with depression (3). Because the original study included UKB data, we conducted a new meta-analysis excluding individuals from UKB to avoid biases due to sample overlap. The resulting meta-analysis contained 118 811 cases and 327 427 controls and identified 23 independent loci.

b) **ADHD**: GWAS meta-analysis of 20 183 ADHD cases and 35 191 controls identified 12 independent loci surpassing genome-wide significance (4). Only the European ancestry meta-analysis (19 099 cases and 34 194 controls) was used to calculate the genetic scores.

c) **Schizophrenia**. Results from the second Psychiatric Genomics Consortium (PGC) schizophrenia mega-analysis included up to 36 989 cases and 113 075 controls and identified 108 schizophrenia associated genetic loci (5).

The software PRSice2 (<https://choishingwan.github.io/PRSice/>) was used to calculate the PRSs (6). For computational reasons, directly genotyped variants were used in the UKB dataset. Preliminary analyses demonstrated that due to clumping of variants, results from genotyped vs imputed data are similar (not shown).

Ten p-value thresholds were used to compute the scores: 0.00000005; 0.000001; 0.0001; 0.001; 0.01; 0.05; 0.1; 0.2; 0.5 and 1. SNPs were selected if they had imputation INFO scores >0.6 (for depression), and >0.7 (for SCZ and ADHD), minor allele frequency >0.01 (for ADHD and SCZ) or >0.005 (for depression), and low linkage disequilibrium to each other (r2 < 0.1 within 250kb to both ends of the index SNP). For the dataset from UKB, we selected SNPs with a 90% genotyping rate and minor allele frequency >0.05. The PRSs were calculated under the additive model and standardised to a mean of zero and standard deviation of one to aid interpretation of results. Nagelkerke R2 was used to calculate the variance explained by the PRSs. However this metric suffers from bias when the proportion for cases controls is not reflective of the case population prevalence (7). Since there is evidence of a healthy volunteer selection bias in the UKB cohort (8), ascertainment biases of the R2 were adjusted in PRSice by providing population prevalence information for the binary phenotypes. Population prevalences were obtained from World Health Organisation World Mental Health Surveys (9): Lifetime prevalence of ever having a psychotic experience was set as 5.8%, hallucinations as 5.2% and delusional experiences as 1.3%. For maternal smoking, population prevalence was defined as [Ncases]/[Ntotal completing MHQ] and sample prevalence was defined as [Ncases/(Ncases + Ncontrols)]. This estimate was calculated as previously described (10) and might represent better the prevalence of smoking during pregnancy 50 years ago. Significance for the PRS association was declared at the p-value threshold of 0.005 (Bonferroni correction based on 9 independent tests, one for each p-value threshold analysed).

**PRS power calculation**

We performed power calculations for the polygenic analysis at each p-value threshold using the R package AVENGEME (11). Models assumed SNP heritability of 0.216 for ADHD (4), 0.33 for schizophrenia (5) and 0.085 for depression (12). The lifetimes prevalence used were 5% for ADHD (13), 0.87% for schizophrenia (14), 16.2% for depression(15), 5.8% for ever having a psychotic experience, 5.2% for hallucinations and 1.3% for delusions (9). The models used for power calculation assumed that the markers are independent.

Since all the PRS analyses were cross-trait, four hypothetical scenarios were tested, comparing change in statistical power when covariance between genetic effects in training and test samples were 25%, 50%, 75% and 100%.

All the PRS analyses performed under all the hypothetical scenarios gave >95% power.

**Supplementary results**

**Supplementary Table 7.** Phenotypic correlations between smoking and psychotic experiences after quality control.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Participants with genomic data after QC** | | | | | |
| **N** | **Maternal Smoking =Yes (%)** | **Current Smokers (%)** | **Former Smokers (%)** | **Never smoked (%)** | **Mean packs per year (SE)** |
| **Any psychotic experience** | *Cases* | 7 419 | 2 126  (28.7%) | 775  (10.4%) | 2 732  (36.8%) | 3 616  (48.7%) | 22.0  (0.36) |
| *Controls* | 137 695 | 33 769  (24.5%) | 9 139  (6.6%) | 46 692  (33.9%) | 75 547  (54.9%) | 20.0  (0.09) |
| **Delusions** | *Cases* | 1 879 | 547  (29.1%) | 237  (12.6%) | 693  (36.9%) | 872  (46.4%) | 23.0  (0.67) |
| *Controls* | 143 145 | 35 330  (24.7%) | 9 667  (6.8%) | 48 695  (34.0%) | 78 250  (54.7%) | 20.1  (0.08) |
| **Hallucinations** | *Cases* | 6 164 | 1 778  (28.8%) | 647  (10.5%) | 2 254  (36.6%) | 3 016  (48.9%) | 21.7  (0.38) |
| *Controls* | 138 654 | 34 048  (24.6%) | 9 241  (6.7%) | 47 060  (33.9%) | 76 002  (54.8%) | 20.0  (0.09) |

A screenshot of a cell phone

Description automatically generated

**Supplementary Figure 1**. Prediction of psychotic experiences in UKB using PRSs for schizophrenia (Panel A), depression (Panel B) and ADHD (Panel C). Each panel is divided by the type of psychotic experiences. Y axis represents variance explained in the liability scale (Nagelkerke R2). X axis represents results at different PRS-value thresholds. Association p-values are listed above of the bars.

A)

![A screenshot of a cell phone

Description automatically generated]()

B)

![A picture containing screenshot

Description automatically generated]()

C)

![A screenshot of a cell phone

Description automatically generated]()

**Supplementary Figure 2:** Prediction of smoking behaviours in UKB using PRSs for schizophrenia (Panel A), depression (Panel B) and ADHD (Panel C). Each panel is divided by the type of smoking behaviour phenotype. Logistic regression models were calculated using PRSice-2 to assess the association between the PRSs and former vs current smoker, never vs current smoker, never vs former smoker, and maternal smoking around the participants birth. As the number of packs smoked per year represent count data, Poisson regression models were constructed in R to assess the association between the PRSs and number of packs smoked per year. Y axis represents variance explained (Nagelkerke R2) in the liability scale. X axis represents results at different PRS p-value thresholds. Association p-values are listed above of the bars.

**Supplementary Table 8**. Interaction effects between PRSs and smoking status (never vs former vs current) on psychotic experiences (delusions, hallucinations or any of these two). Interaction effects are on the multiplicative (OR) and additive scale (β). Results are reported at the p-value threshold with the highest R2 in in main PRS analyses (*p*=0.2).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Predictor** | ***Multiplicative*** *(logistic regression)* | | | ***Additive*** *(linear regression)* | | |
| **OR** | **95%CI** | ***p*** | **β** | **Std. Error** | ***p*** |
| ***Any psychotic experience*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.29 | 1.07-1.56 | 0.008174 | 1.182 x 10-2 | 4.970 x 10-3 | 0.017401 |
| Former vs never smokers | 0.91 | 0.71-1.17 | 0.478631 | -5.035 x 10-3 | 6.408 x 10-3 | 0.432053 |
| Current vs never smokers | 1.43 | 0.98-2.07 | 0.059050 | 2.444 x 10-2 | 1.111 x 10-2 | 0.027825 |
| PRS(SCZ) x former smokers | 1.04 | 0.95-1.14 | 0.363730 | 3.917 x 10-3 | 2.266 x 10-3 | 0.083958 |
| PRS(SCZ) x current smokers | 0.98 | 0.85-1.13 | 0.779777 | 3.967 x 10-3 | 4.244 x 10-3 | 0.349915 |
| PRS(DEP) at P-value threshold = 0.2 | 1.33 | 1.17-1.50 | 8.09 x 10-6 | 1.452 x 10-2 | 3.272 x 10-3 | 9.16 x 10-6 |
| Former vs never smokers | 1.01 | 0.96-1.08 | 0.450368 | -5.670 x 10-3 | 6.409 x 10-3 | 0.376358 |
| Current vs never smokers | 0.99 | 0.91-1.09 | 0.061811 | 2.399 x 10-2 | 1.111 x 10-2 | 0.030779 |
| PRS(DEP) x former smokers | 1.02 | 0.96-1.08 | 0.572737 | 1.905 x 10-3 | 1.404 x 10-3 | 0.174883 |
| PRS(DEP) x current smokers | 0.99 | 0.91-1.09 | 0.888421 | 3.036 x 10-3 | 2.635 x 10-3 | 0.249182 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.12 | 0.99-1.27 | 0.06544 | 5.499 x 10-3 | 3.255 x 10-3 | 0.09116 |
| Former vs never smokers | 0.91 | 0.71-1.17 | 0.46853 | -5.351 x 10-3 | 6.418 x 10-3 | 0.40441 |
| Current vs never smokers | 1.41 | 0.96-2.03 | 0.07427 | 2.388 x 10-2 | 1.113 x 10-2 | 0.03189 |
| PRS(ADHD) x former smokers | 1.00 | 0.95-1.05 | 0.96207 | 3.795 x 10-4 | 1.356 x 10-3 | 0.77960 |
| PRS(ADHD) x current smokers | 1.04 | 0.96-1.14 | 0.29890 | 5.010 x 10-3 | 2.512 x 10-3 | 0.04613 |
| ***Hallucinations*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.24 | 1.00-1.53 | 0.046345 | 8.176 x 10-3 | 4.559 x 10-3 | 0.072928 |
| Former vs never smokers | 0.97 | 0.74-1.28 | 0.846827 | -1.533 x 10-3 | 5.881 x 10-3 | 0.794277 |
| Current vs never smokers | 1.27 | 0.83-1.92 | 0.261589 | 1.296 x 10-2 | 1.019 x 10-2 | 0.203709 |
| PRS(SCZ) x former smokers | 1.04 | 0.94-1.15 | 0.435497 | 2.899 x 10-3 | 2.080 x 10-3 | 0.163324 |
| PRS(SCZ) x current smokers | 0.95 | 0.81-1.11 | 0.496077 | 4.676 x 10-4 | 3.894 x 10-3 | 0.904404 |
| PRS(DEP) at P-value threshold = 0.2 | 1.32 | 1.15-1.52 | 6.62 x 10-5 | 1.159 x 10-2 | 3.003 x 10-3 | 0.000113 |
| Former vs never smokers | 0.97 | 0.74-1.27 | 0.829991 | -2.036 x 10-3 | 5.882 x 10-3 | 0.729192 |
| Current vs never smokers | 1.28 | 0.84-1.94 | 0.240235 | 1.259 x 10-2 | 1.019 x 10-2 | 0.216444 |
| PRS(DEP) x former smokers | 1.00 | 0.94-1.06 | 0.972918 | 8.890 x 10-4 | 1.289 x 10-3 | 0.490336 |
| PRS(DEP) x current smokers | 0.92 | 0.83-1.02 | 0.099946 | -1.769 x 10-3 | 2.419 x 10-3 | 0.464589 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.13 | 0.98-1.29 | 0.093425 | 4.513 x 10-3 | 2.986 x 10-3 | 0.13077 |
| Former vs never smokers | 0.97 | 0.74-1.28 | 0.853878 | -1.712 x 10-3 | 5.890 x 10-3 | 0.77134 |
| Current vs never smokers | 1.26 | 0.82-1.90 | 0.276445 | 1.254 x 10-2 | 1.021 x 10-2 | 0.21924 |
| PRS(ADHD) x former smokers | 0.97 | 0.91-1.03 | 0.274782 | -9.471 x 10-4 | 1.244 x 10-3 | 0.44655 |
| PRS(ADHD) x current smokers | 0.99 | 0.89-1.08 | 0.755347 | 1.041 x 10-3 | 2.306 x 10-3 | 0.65176 |
| ***Delusions*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.37 | 0.94-1.98 | 0.0955 | 3.655 x 10-3 | 2.552 x 10-3 | 0.152147 |
| Former vs never smokers | 0.72 | 0.44-1.18 | 0.1970 | -4.435 x 10-3 | 3.291 x 10-3 | 0.177755 |
| Current vs never smokers | 2.08 | 1.09-3.76 | 0.0195 | 1.936 x 10-2 | 5.704 x 10-3 | 0.000687 |
| PRS(SCZ) x former smokers | 1.02 | 0.85-1.22 | 0.8253 | 1.534 x 10-3 | 1.164 x 10-3 | 0.187645 |
| PRS(SCZ) x current smokers | 0.98 | 0.75-1.28 | 0.8951 | 4.709 x 10-3 | 2.180 x 10-3 | 0.030753 |
| PRS(DEP) at P-value threshold = 0.2 | 1.25 | 0.99-1.58 | 0.05919 | 3.862 x 10-3 | 1.681 x 10-3 | 0.021577 |
| Former vs never smokers | 0.72 | 0.44-1.16 | 0.18142 | -4.667 x 10-3 | 3.292 x 10-3 | 0.156301 |
| Current vs never smokers | 2.02 | 1.06-3.68 | 0.02576 | 1.917 x 10-2 | 5.703 x 10-3 | 0.000774 |
| PRS(DEP) x former smokers | 0.72 | 0.44-1.16 | 0.12162 | 1.526 x 10-3 | 7.214 x 10-4 | 0.034431 |
| **PRS(DEP) x current smokers** | 2.02 | 1.06-3.68 | 0.06714 | **5.176 x 10-3** | **1.354 x 10-3** | **0.000132** |
| PRS(ADHD) at P-value threshold = 0.2 | 1.05 | 0.84-1.32 | 0.656602 | 6.638 x 10-4 | 1.672 x 10-3 | 0.691301 |
| Former vs never smokers | 0.73 | 0.45-1.18 | 0.201909 | -4.565 x 10-3 | 3.296 x 10-3 | 0.166047 |
| Current vs never smokers | 2.01 | 1.06-3.66 | 0.026040 | 1.926 x 10-2 | 5.714 x 10-3 | 0.000752 |
| PRS(ADHD) x former smokers | 1.05 | 0.95-1.17 | 0.343882 | 7.083 x 10-4 | 6.964 x 10-4 | 0.309129 |
| **PRS(ADHD) x current smokers** | 1.23 | 1.05-1.44 | 0.008462 | **5.004 x 10-3** | **1.290 x 10-3** | **0.000106** |

Note. All analyses included the first ten principal components, genotyping batch and the interaction between those and smoking status and PRS as covariates (16). Results from each of these covariates were not of interest to the study and are therefore not displayed. Also, due to the inclusion of interaction terms in this model, main effects should be interpreted as conditional on the interacting variables. The main effects of PRSs and smoking status are reported in Table 1 and Supplementary Figure 1.

***Sensitivity analysis – Exclusion of individuals with psychotic disorders***

To assess the impact that people diagnosed with psychotic disorders may have on interaction between PRSs and smoking status on delusions, we performed sensitivity analysis focusing on individuals that did *not* have diagnosis of psychotic disorders.

Individuals reporting delusions were ascertained as indicated in Supplementary Table 1, but participants reporting psychotic disorders were excluded (Assigned as NA). We next repeated the interaction between PRSs and smoking status on lifetime occurrence of delusions.

**Supplementary Table 9.** Number of individuals with psychotic disorders that were excluded.

|  |  |  |  |
| --- | --- | --- | --- |
| **Phenotype** | **Sample size after genetic QC** | **Individuals with psychotic disorders excluded** | **Final sample size** |
| **Lifetime delusions** | *Controls* = 143 145  *Cases* = 1 879  **Total = 145 024** | 1 388  *(443 cases + 1 336 controls)* | *Controls* = 141 809  *Cases* = 1 436  **Total = 143 245** |

**A close up of a map

Description automatically generated**

**Supplementary Figure 3**. Sensitivity analyses, excluding individuals with diagnosis of psychotic disorders. Figure shows associations between PRSs for A) depression and B) ADHD, and occurrence of delusions. Current smokers are shown as blue squares, former smokers as orange triangles, and never smokers as green circles. P values for the PRS x smoking status interactions are shown on the upper part of each plot. Associations between smoking status and the PRSs (*p*<0.0028) on the additive scale remained significant after exclusion of participants with psychotic disorders.

**Supplementary Table 10**. Interaction effects between PRSs and smoking status (never vs former vs current) on delusions. Interaction effects are on the additive scale (β). Results are reported at the p-value threshold with the highest R2 in main PRS analyses (*p*=0.2).

|  |  |  |  |
| --- | --- | --- | --- |
| **Predictor** | ***Additive*** *(linear regression)* | | |
| **β** | **Std. Error** | ***p*** |
| PRS(DEP) at P-value threshold = 0.2 | 2.437 x 10-3 | 1.490 x 10-3 | 0.10184 |
| Former vs never smokers | -4.698 x 10-3 | 2.917 x 10-3 | 0.10728 |
| Current vs never smokers | 6.979 x 10-3 | 5.071 x 10-3 | 0.16876 |
| PRS(DEP) x former smokers | 1.392 x 10-3 | 6.382 x 10-4 | 0.02916 |
| **PRS(DEP) x current smokers** | **3.757 x 10-3** | **1.204 x 10-3** | **0.00180** |
| PRS(ADHD) at P-value threshold = 0.2 | 4.874 x 10-4 | 1.480 x 10-3 | 0.741882 |
| Former vs never smokers | -4.713 x 10-3 | 2.920 x 10-3 | 0.106549 |
| Current vs never smokers | 6.782 x 10-3 | 5.082 x 10-3 | 0.182024 |
| PRS(ADHD) x former smokers | 8.480 x 10-4 | 6.159 x 10-4 | 0.168569 |
| **PRS(ADHD) x current smokers** | **4.538 x 10-3** | **1.147 x 10-3** | **7.62 x 10-5** |

Note. All analyses included the first ten principal components, genotyping batch and the interaction between those and smoking status and PRS as covariates (16). Results from each of these covariates were not of interest to the study and are therefore not displayed. Also, due to the inclusion of interaction terms in this model, main effects should be interpreted as conditional on the interacting variables. The main effects of PRSs and smoking status are reported in Table 1 and Supplementary Figure 1.

**Supplementary Table 11**. Interaction effects between PRSs and maternal smoking on psychotic experiences (delusions, hallucinations or any of these two). Interaction effects are on the multiplicative (OR) and additive scale (β). Results are reported at the p-value threshold with the highest R2 in in main PRS analyses (*p*=0.2).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Predictor** | ***Multiplicative*** *(logistic regression)* | | | ***Additive*** *(linear regression)* | | |
| **OR** | **95%CI** | ***p*** | **β** | **Std. Error** | ***p*** |
| ***Any psychotic experience*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.31 | 1.06-1.60 | 0.0100 | 1.264 x 10-2 | 5.264 x 10-3 | 0.0163 |
| Maternal smoking = YES | 1.40 | 1.08-1.81 | 0.0105 | 1.887 x 10-2 | 6.958 x 10-3 | 0.0067 |
| PRS(SCZ) x Maternal smoking = YES | 0.95 | 0.86-1.04 | 0.2764 | -5.800 x 10-4 | 2.490 x 10-3 | 0.8158 |
| PRS(DEP) at P-value threshold = 0.2 | 1.34 | 1.17-1.53 | 1.42 x 10-5 | 1.513 x 10-2 | 3.453 x 10-3 | 1.17 x 10-5 |
| Maternal smoking = YES | 1.36 | 1.05-1.76 | 0.0191 | 1.793 x 10-2 | 6.955 x 10-3 | 0.0099 |
| PRS(DEP) x Maternal smoking = YES | 1.01 | 0.95-1.07 | 0.8002 | 1.906 x 10-3 | 1.547 x 10-3 | 0.2181 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.13 | 0.99-1.30 | 0.0665 | 5.993 x 10-3 | 3.455 x 10-3 | 0.0829 |
| Maternal smoking = YES | 1.39 | 1.07-1.79 | 0.0133 | 1.892 x 10-2 | 6.954 x 10-3 | 0.0065 |
| PRS(ADHD) x Maternal smoking = YES | 0.97 | 0.92-1.03 | 0.3185 | -6.253 x 10-4 | 1.486 x 10-3 | 0.6740 |
| ***Hallucinations*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.23 | 0.98-1.55 | 0.0718 | 7.986 x 10-3 | 4.828 x 10-3 | 0.0981 |
| Maternal smoking = YES | 1.44 | 1.08-1.91 | 0.0131 | 1.651 x 10-2 | 6.381 x 10-3 | 0.0097 |
| PRS(SCZ) x Maternal smoking = YES | 0.97 | 0.88-1.08 | 0.6274 | 4.919 x 10-4 | 2.284 x 10-3 | 0.8295 |
| PRS(DEP) at P-value threshold = 0.2 | 1.34 | 1.15-1.55 | 0.0001 | 1.187 x 10-2 | 3.167 x 10-3 | 0.0002 |
| Maternal smoking = YES | 1.41 | 1.06-1.86 | 0.0190 | 1.590 x 10-2 | 6.378 x 10-3 | 0.0127 |
| PRS(DEP) x Maternal smoking = YES | 1.00 | 0.93-1.07 | 0.9412 | 1.116 x 10-3 | 1.420 x 10-3 | 0.4319 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.11 | 0.96-1.29 | 0.1683 | 3.863 x 10-3 | 3.169 x 10-3 | 0.2228 |
| Maternal smoking = YES | 1.43 | 1.07-1.89 | 0.0150 | 1.672 x 10-2 | 6.376 x 10-3 | 0.0087 |
| PRS(ADHD) x Maternal smoking = YES | 0.99 | 0.93-1.06 | 0.7802 | 4.108 x 10-4 | 1.364 x 10-3 | 0.7632 |
| ***Delusions*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.39 | 0.93-2.03 | 0.1031 | 4.255 x 10-3 | 2.695 x 10-3 | 0.1144 |
| Maternal smoking = YES | 1.19 | 0.72-1.92 | 0.4920 | 4.591 x 10-3 | 3.562 x 10-3 | 0.1975 |
| PRS(SCZ) x Maternal smoking = YES | 0.86 | 0.71-1.05 | 0.1319 | -7.001 x 10-4 | 1.275 x 10-3 | 0.5828 |
| PRS(DEP) at P-value threshold = 0.2 | 1.33 | 1.04-1.69 | 0.0243 | 4.733 x 10-3 | 1.768 x 10-3 | 0.0074 |
| Maternal smoking = YES | 1.13 | 0.69-1.83 | 0.6161 | 4.406 x 10-3 | 3.561 x 10-3 | 0.2160 |
| PRS(DEP) x Maternal smoking = YES | 1.03 | 0.92-1.16 | 0.5867 | 1.124 x 10-3 | 7.925 x 10-4 | 0.1563 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.10 | 0.85-1.40 | 0.4758 | 1.199 x 10-3 | 1.769 x 10-3 | 0.4978 |
| Maternal smoking = YES | 1.16 | 0.71-1.88 | 0.5400 | 4.647 x 10-3 | 3.560 x 10-3 | 0.1918 |
| PRS(ADHD) x Maternal smoking = YES | 0.94 | 0.85-1.06 | 0.3620 | -4.894 x 10-4 | 7.611 x 10-4 | 0.5202 |

Note. All analyses included the first ten principal components, genotyping batch and the interaction between those and maternal smoking and PRS as covariates (16). Results from each of these covariates were not of interest to the study and are therefore not displayed. Also, due to the inclusion of interaction terms in this model, main effects should be interpreted as conditional on the interacting variables. The main effects of PRSs and maternal smoking are reported in Table 1 and Supplementary Figure 1.

**Supplementary Table 12**. Interaction effects between PRSs and the number of packs smoked per year on psychotic experiences (delusions, hallucinations or any of these two). Interaction effects are on the multiplicative (OR) and additive scale (β). Results are reported at the p-value threshold with the highest R2 in in main PRS analyses (*p*=0.2).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Predictor** | ***Multiplicative*** *(logistic regression)* | | | ***Additive*** *(linear regression)* | | |
| **OR** | **95%CI** | ***p*** | **β** | **Std. Error** | ***p*** |
| ***Any psychotic experience*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.50 | 1.07-2.08 | 0.0165 | 2.161 x 10-2 | 1.013 x 10-2 | 0.0329 |
| Number of packs per year | 1.02 | 1.01-1.03 | 0.0004 | 1.391 x 10-3 | 3.754 x 10-4 | 0.0002 |
| PRS(SCZ) x Number of packs per year | 1.00 | 1.00-1.01 | 0.6017 | 1.651 x 10-4 | 1.344 x 10-4 | 0.2195 |
| PRS(DEP) at P-value threshold = 0.2 | 1.32 | 1.06-1.65 | 0.0141 | 1.545 x 10-2 | 6.827 x 10-3 | 0.0237 |
| Number of packs per year | 1.02 | 1.01-1.03 | 0.0012 | 1.322 x 10-3 | 3.759 x 10-4 | 0.0004 |
| PRS(DEP) x Number of packs per year | 1.00 | 0.99-1.00 | 0.1972 | 1.809 x 10-4 | 8.292 x 10-5 | 0.0291 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.28 | 1.04-1.57 | 0.0185 | 1.459 x 10-2 | 6.523 x 10-3 | 0.0253 |
| Number of packs per year | 1.02 | 1.01-1.03 | 0.0008 | 1.320 x 10-3 | 3.772 x 10-4 | 0.0005 |
| PRS(ADHD) x Number of packs per year | 1.00 | 0.996-1.002 | 0.6109 | -1.326 x 10-5 | 8.202 x 10-5 | 0.8716 |
| ***Hallucinations*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.54 | 1.07-2.19 | 0.0172 | 2.032 x 10-2 | 9.307 x 10-3 | 0.0290 |
| Number of packs per year | 1.01 | 1.00-1.03 | 0.0219 | 8.223 x 10-4 | 3.452 x 10-4 | 0.0172 |
| PRS(SCZ) x Number of packs per year | 1.00 | 1.00-1.01 | 0.2756 | 2.006 x 10-4 | 1.235 x 10-4 | 0.1045 |
| PRS(DEP) at P-value threshold = 0.2 | 1.22 | 0.95-1.55 | 0.1109 | 9.337 x 10-3 | 6.282 x 10-3 | 0.1372 |
| Number of packs per year | 1.01 | 1.00-1.02 | 0.0361 | 7.685 x 10-4 | 3.457 x 10-4 | 0.0262 |
| PRS(DEP) x Number of packs per year | 1.00 | 0.99-1.00 | 0.1759 | 1.443 x 10-4 | 7.623 x 10-5 | 0.0584 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.24 | 0.98-1.55 | 0.0576 | 1.078 x 10-2 | 5.996 x 10-3 | 0.0723 |
| Number of packs per year | 1.01 | 1.00-1.03 | 0.0265 | 7.746 x 10-4 | 3.468 x 10-4 | 0.0255 |
| PRS(ADHD) x Number of packs per year | 1.00 | 0.996-1.001 | 0.4402 | -5.297 x 10-5 | 7.537 x 10-5 | 0.4822 |
| ***Delusions*** | | | | | | |
| PRS(SCZ) at P-value threshold = 0.2 | 1.77 | 0.94-3.23 | 0.0704 | 8.805 x 10-3 | 5.386 x 10-3 | 0.1021 |
| Number of packs per year | 1.01 | 0.99-1.03 | 0.1415 | 3.336 x 10-4 | 1.997 x 10-4 | 0.0949 |
| PRS(SCZ) x Number of packs per year | 0.99 | 0.99-1.00 | 0.2093 | -2.547 x 10-5 | 7.153 x 10-5 | 0.7218 |
| PRS(DEP) at P-value threshold = 0.2 | 1.52 | 1.04-2.18 | 0.0271 | 7.913 x 10-3 | 3.631 x 10-3 | 0.0293 |
| Number of packs per year | 1.01 | 0.99-1.03 | 0.1615 | 3.100 x 10-4 | 2.000 x 10-4 | 0.1212 |
| PRS(DEP) x Number of packs per year | 1.00 | 0.99-1.00 | 0.9568 | 4.754 x 10-5 | 4.413 x 10-5 | 0.2813 |
| PRS(ADHD) at P-value threshold = 0.2 | 1.23 | 0.84-1.75 | 0.2817 | 4.032 x 10-3 | 3.468 x 10-3 | 0.2450 |
| Number of packs per year | 1.01 | 0.99-1.03 | 0.1672 | 3.069 x 10-4 | 2.006 x 10-4 | 0.1261 |
| PRS(ADHD) x Number of packs per year | 1.00 | 1.00-1.01 | 0.8026 | 4.142 x 10-5 | 4.362 x 10-5 | 0.3424 |

Note. All analyses included the first ten principal components, genotyping batch and the interaction between those and the number of packs smoked per year and PRS as covariates (16). Results from each of these covariates were not of interest to the study and are therefore not displayed. Also, due to the inclusion of interaction terms in this model, main effects should be interpreted as conditional on the interacting variables. The main effects of PRSs and the number of packs smoked per year are reported in Table 1 and Supplementary Figure 1.

**SUPPLEMENTARY REFERENCES**

1. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in UK Biobank: development, implementation and results from an online questionnaire completed by 157 366 participants. BJPsych Open. 2018 May;4(3):83–90.

2. Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen H-U. The World Health Organization Composite International Diagnostic Interview short-form (CIDI-SF). International Journal of Methods in Psychiatric Research. 1998;7(4):171–85.

3. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018 May;50(5):668–81.

4. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019 Jan;51(1):63–75.

5. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 Jul;511(7510):421–7.

6. Choi SW, O’Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience. 2019 01;8(7).

7. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet. 2011 Mar 11;88(3):294–305.

8. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017 Nov 1;186(9):1026–34.

9. McGrath JJ, Saha S, Al-Hamzawi A, Alonso J, Bromet EJ, Bruffaerts R, et al. Psychotic Experiences in the General Population: A Cross-National Analysis Based on 31,261 Respondents From 18 Countries. JAMA Psychiatry. 2015 Jul;72(7):697–705.

10. Hodgson K, Coleman JR, Hagenaars SP, Purves KL, Choi SWL, O’Reilly PF, et al. Cannabis use, depression and self-harm: phenotypic and genetic relationships. bioRxiv. 2019 Feb 14;549899.

11. Palla L, Dudbridge F. A Fast Method that Uses Polygenic Scores to Estimate the Variance Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting a Trait. The American Journal of Human Genetics. 2015 Aug 6;97(2):250–9.

12. Howard DM, Adams MJ, Shirali M, Clarke T-K, Marioni RE, Davies G, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun. 2018 Apr 16;9(1):1–10.

13. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942–8.

14. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007 Jan;64(1):19–28.

15. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003 Jun 18;289(23):3095–105.

16. Keller MC. Gene × Environment Interaction Studies Have Not Properly Controlled for Potential Confounders: The Problem and the (Simple) Solution. Biological Psychiatry. 2014 Jan 1;75(1):18–24.